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In the manuscript by Di Lullo et al. [1], the authors evaluate the
association between cardiac valve calciﬁcation extent and bio-
chemical markers of mineral metabolism and inﬂammation,
such as parathyroid hormone (PTH), phosphate (P), calcium
(Ca), ﬁbroblast growth factor 23 (FGF23), Klotho, vitamin D and
C-reactive protein, in a population of incident chronic kidney dis-
ease (CKD) stage 3–4 patients. Interestingly, in the multivariate
analysis, high serum PTH and FGF23 levels associated with aortic
valve calciﬁcation. Authors’ conclusions are that further studies
‘should examinewhether FGF23 assay should be included in rou-
tine clinical evaluation of CKD, as part of CV risk stratiﬁcation’.
How far away are we from suggesting routinely screening for
FGF23 in the CKD population?
CKD patients have a dramatically higher incidence of cardio-
vascular morbidity and mortality compared with the general
population [2]. In the last 10 years, several studies have pointed
out that vascular calciﬁcation is a major cause of cardiovascular
disease in the dialysis population. In CKD patients, high levels of
plasma Ca, serum P, PTH and FGF23 play a critical role in the
pathogenesis of cardiovascular events [3].
Patients develop extensive medial calciﬁcation, which causes
increased arterial stiffness and highmorbidity andmortality due
to cardiovascular events [4, 5]. A variety of risk factors are asso-
ciatedwith vascular calciﬁcation in dialysis patients (time ondia-
lysis, uraemic toxins, history of diabetes and inﬂammation), but
abnormalities in bone mineral metabolism may play a critical
role [6]. In fact, elevated serum P, Ca–P product, PTH and FGF23
levels contribute to vascular calciﬁcation, although their roles
are incompletely understood [7, 8]. Elevations of serum P and
Ca–P product levels may worsen cardiovascular events in the
uraemic population, through a progressive increase in Ca depos-
ition in the coronary arteries and heart valves [9].
Recent insights into novel roles of bone biomarkers, such as
FGF23, in vascular biology make this primarily kidney-derived
protein a possible candidate to form a link between bone and
cardiovascular morbidity and mortality [10]. A central aspect of
FGF23 and α-Klotho is regulation of their expression and the
apparent disconnect between tissue level and concentration in
blood. FGF23 is regulated by several feedback loops consistent
with endocrine systems: it reduces serum P, 1,25-dihydroxyvita-
min D and PTH, and these factors stimulate FGF23 expression in
bone. Active vitamin D is the most potent regulator of FGF23 and
acts directly on FGF23 gene transcription by binding a vitamin
D-responsive element in the gene promoter region [11].
FGF23 is now considered a major determinant of circulating
levels of P and vitamin D metabolites. This role is accomplished
by regulation of the expression of transmembrane P carriers and
by modulating activity of the hydroxylases that activate or cata-
bolize vitamin D. All of these FGF23 effects are obtained through
activation of speciﬁc receptors. Signiﬁcantly, however, the pres-
ence of a co-receptor is essential. Intriguingly, this co-receptor,
Klotho, besides contributing to FGF23 actions, also has speciﬁc
biological effects that may be relevant for cardiovascular disease
in CKD.
Several small clinical studies report on the association be-
tween higher levels of FGF23 and vascular calciﬁcation. Increased
serum levels of FGF23 have been recognized as a risk factor for
mortality either in conservative or in maintenance haemodialy-
sis populations [12, 13]. Recently, a prospective study of patients
with CKD stages 3–5D, with a follow-up of 35 ± 3months, showed
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a signiﬁcant positive correlation between serumFGF23 levels and
coronary calciﬁcation (CAC) score, with a 62.5% sensitivity and a
75.9% speciﬁcity. In this study, regression analysis identiﬁed
FGF23 levels together with severe CAC (>400) as independent
risk factors for all-causemortality [14]. Cardiac valve calciﬁcation
is a common ﬁnding in CKD with a high rate of cardiovascular
mortality [15].
Even if in the preclinical setting the role of FGF23 in vascular
calciﬁcation pathogenesis is still unclear, interestingly, high FGF-
23 levels were independent predictors of mitral valve calciﬁca-
tion and a risk factor for cardiovascular mortality in 150 diabetic
patients with mild to moderate CKD [16]. A relevant contribution
on the possible pathogenetic role of FGF23 in the development of
cardiovascular disease in renal patients comes from the work by
Faul et al. [17]. In this study, increased levels of FGF23 were inde-
pendently associated with left ventricular hypertrophy (LVH) in a
large CKD population. Importantly, with in vivo experimental
data, LVH was induced by an intramyocardial or intravenous in-
jection of FGF23 in wild-type mice. LVH developed also in trans-
genic Klotho-deﬁcient mice with mildly elevated FGF23 levels.
Finally, in ex vivo studies (isolated cardiomyocytes), these authors
demonstrated a direct hypertrophic effect of FGF23 through
interaction with an FGF receptor that activates the calcineurin–
nuclear factor of activated T-cells signalling pathway, independ-
ently of the presence of the co-receptor Klotho. In an established
animal model of CKD, treatment with an FGF receptor blocker
attenuated LVH, with no signiﬁcant change in blood pressure.
All of these data point to a causal role for FGF23, which seems
to be Klotho-independent, in the pathogenesis of LVH. Accord-
ingly, chronically elevated FGF23, as described in CKD, could
directly contribute to LVH and high rates of cardiovascular mor-
tality in these patients [17].
Lower levels of FGF23 resulting from therapies aimed at con-
trolling CKD-MBD were associated with lower rates of cardiovas-
cular events [18]. The clinical signiﬁcance of FGF23 as a biomarker
of CKD-MBD or of cardiovascular risk in renal patients is thus
waiting for deﬁnite settlement.
Besides FGF23, also its co-receptor Klotho is now widely in-
vestigated for potential involvement with cardiovascular disease
through direct or indirect mechanisms. Available data indicate
the strict pathophysiological link existing between FGF23 and
Klotho. Even very early reduction in renal function associates
with reduced circulating levels of Klotho (which is mainly pro-
duced by the kidney). It is currently accepted that this reduction
prompts an increment of FGF23 secretion tentatively aimed at
balancing the peripheral resistance secondary to reduction of
the co-receptor. As a result, it may well be that at least some of
the cardiovascular disease of CKD is secondary to reduced Klotho
systemic activity. In fact, Klotho exists in a membrane-bound
form and a soluble form (s-Klotho). Transmembrane α-Klotho
(TM-Klotho), expressed in renal tubules, is mainly regarded as
the cofactor for FGF23 receptor. Circulating soluble α-Klotho
(s-Klotho) results from TM-Klotho shedding and is regarded as
the component of Klotho that is responsible for its systemic, spe-
ciﬁc and FGF23-independent effect. Decreased TM-Klotho ex-
pression, described in both experimental and human CKD,
lowers FGF23 effects on kidney tubules, but also lessens circulat-
ing s-Klotho [19]. In CKD patients, circulating s-Klotho is lower
than normal and its reduction is detectable from CKD stage
2. s-Klotho positively correlates with eGFR, but also with serum
Ca and, negatively, with serum P, PTH and FGF23. In this setting,
serum levels of FGF23 are also higher than normal, with in-
crements detectable from CKD stage 2. Assuming that s-Klotho
mirrors TM-Klotho synthesis, low-circulating s-Klotho somehow
describes the ensuing tubular resistance to FGF23, which, accord-
ingly, is increased as a secondary response [20]. Thus, levels of s-
Klotho can be regarded as an earlymarker of CKD-MBD, butmore
reliability of current assays for s-Klotho is needed.
In conclusion, since FGF23 is reliably measured in serum or
plasma, a wealth of epidemiological studies have explored cross-
sectional and longitudinal relationships between FGF23 and clin-
ical outcomes. Theoutcomeof these studiesunequivocally points
to FGF23 as a robust marker of disease surrogate markers as well
as hard clinical end points includingmortality and cardiovascular
events. Such relationships should be conﬁrmed in CKD patients
as well as in community-dwelling adults and in populations
with a high occurrence of pre-existing cardiovascular disease.
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(See related article byDi Lullo et al. Fibroblast growth factor 23 and
parathyroid hormone predict extent of aortic valve calciﬁcations
in patients with mild to moderate chronic kidney disease. Clin
Kidney J (2015) 8: 732–736.)
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